UC Davis uses SAINT therapy for depression
A new therapy is showing impressive results for people with treatment-resistant depression, a condition where symptoms persist even…
Compass CEO Kabir Nath quit high-paying job to work on psychedelic pill for treating depression
In 2022, Kabir Nath quit his high-paying executive job at a pharmaceutical company to tackle a project that…
3 Companies Redefining Healthcare Innovation
This article was originally published on ETFTrends.com. The Healthcare Technology and Innovation index (HTEC) was launched back in…
Does FDA’s Rolling Review Of COMP360 Psilocybin Depression Therapy Change The Bull Case For COMPASS Pathways (CMPS)?
In April 2026, COMPASS Pathways announced that the FDA granted a rolling NDA review for its synthetic psilocybin…
AtaiBeckley’s BPL-003 Depression Data Sharpen Clinical Path And Investor Focus
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. AtaiBeckley…
Ketamine Revolution: Study Redefines Depression Treatment
Summary: For decades, the standard treatment for depression relied on antidepressants that targeted monoamines like serotonin and norepinephrine—drugs…
Implant provides lasting relief for treatment-resistant depression – WashU Medicine
Visit the News Hub Study finds enduring benefits of vagus nerve stimulation for patients not helped by standard…
DNA test boosts recovery in treatment-resistant depression
A major new meta-analysis shows that a DNA test guiding antidepressant choice boosts recovery odds in treatment-resistant depression,…